Design and formulation of cinnarizine chewing gum for treatment of motion sickness or Ménière's disease

Abstract

Meniere's disease is a chronic condition characterized by severe episodes of vertigo, hearing loss, tinnitus, and auditory pressure. Cinnarizine is a medication that can be used for controlling these symptoms. By reducing vascular contractions and blood viscosity, this medication can effectively manage these symptoms. Currently, medicinal chewing gum (MCG) is a drug delivery system that has made significant advancements in researches and is expected to be produced with superior standards in the future. This drug delivery system can provide drugs or nutrients in the form of a formulation with an extended and continuous release. Objective:The objective of this study is to design and formulate medicinal chewing gum containing cinnarizine for the treatment of Meniere's disease. Additionally, the clinical effects of the obtained formulations will be examined.Materials and Methods:First, a calibration curve for the medication was drawn, and then medicated chewing gums were prepared using suitable base materials. The physicochemical properties of the prepared gums, including hardness, erosion, and physical stability, were examined. The drug release profile from the gum base in a simulated oral environment was evaluated using a specifically designed device that could mimic chewing action. Finally, the clinical clinical effects of formulated chewing gums will be examined on human patients. Conclusion:Upon examination of the erosion, release, content uniformity tests, and clinical evaluatory results, it was found that the formulated chewing gums exhibit comparable clinical efficacy to cinnarizine tablets. Based on the acquired data and favorable advantages of formulated chewing gums in comparison to tablets, this formulation possesses significant potential as an alternative to these pharmaceutical formulations.